# Deltex Medical Group plc South Korean broadens ODM reimbursement

- Link: https://www.directorstalkinterviews.com/deltex-medical-group-plc-south-korean-broadens-odm-reimbursement/412722158
- Published: 2017-01-25T07:11:00+00:00
- Author: Giles Arbor

**Deltex Medical Group plc** (LON:DEMG), the global leader in Oesophageal Doppler
Monitoring (“ODM”), has today announced that the health authorities in South Korea
have decided to increase the range of medical conditions for which they will reimburse
the cost of using ODM.

The previously narrow coverage of specific conditions for hospitals to be reimbursed
for use of ODM in South Korea has been significantly broadened to include all patients
with unstable haemodynamics and this includes the vast majority of major and high
risk surgical patients.

The South Korean reimbursement system sets the price that hospitals pay per patient
for the ODM technology used. The hospital is normally reimbursed 80% of the price
by the government with the remaining 20% billed to the patient.

Sales to the Company’s distributor in Korea were £0.3m in 2016 (2015: £0.2m). With
the broader reimbursement in place, the distributor’s target is to get to end-user
sales of at least 1,000 probes a month by the end of 2018 which would equate to 
annualised Deltex sales of over £0.6m.

> **Ewan Phillips, Deltex Medical Group plc Chief Executive, commented:** “Deltex
> made good progress in South Korea in 2015 and 2016 and this reimbursement decision,
> which is specific to ODM, should allow our distribution partner to increase the
> installed base and probe consumption level during 2017. South Korea is one of 
> the most developed markets for intraoperative fluid management in the world and
> our objectives are both to expand the market and increase ODM’s market share.”

Share on:
